2022-02-07 21:48 Regulatory
Biovica, active in cancer diagnostics, today announces that it has received full feedback from the FDA on its updated 510(k)-application enabling a clear plan for the submission process. Biovica is now aiming for submission in May 2022. As previously...
2021-12-01 07:30 Regulatory Interim
Significant events during the second quarter Significant events after the end of the period Audiocast: When: 1 December 2021 at 3 PM CET Where: https://tv.streamfabriken.com/biovica-international-q2-2021-2022 Phone numbers: SE: +46850558350, DK: +4578150109...
2021-11-24 08:00 Regulatory
Biovica, active in cancer diagnostics, today announces initiation of the TK IMPACT study, an investigator initiated prospective clinical trial at Washington University of St Louis to evaluate the clinical utility of Biovica’s blood-based biomarker...
2021-11-19 16:05 Regulatory
Biovica, active in cancer diagnostics, today announced that results from three different studies using DiviTum®TKa, including a budget impact model, will be presented at the world's largest breast cancer symposium, San Antonio Breast Cancer Symposium...
2021-11-16 09:15 Regulatory
Biovica, active in cancer diagnostics, today announced that the results of a DiviTum®TKa budget impact model have been published in the Journal of Medical Economics. This publication expands on data presented at the ISPOR 2021 meeting. The model’s...
2021-10-12 13:35 Regulatory
The extra general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 12 October 2021 and the following resolutions were passed by the meeting. ELECTION OF THE BOARD OF DIRECTORS The extra general meeting...
2021-09-23 08:00 Regulatory
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting on Tuesday 12 October 2021. Information with respect to the coronavirus The Company is mindful of the health...
2021-09-15 08:00 Regulatory
Biovica, active in cancer diagnostics, today announces that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study have been published in the highly ranked peer-reviewed scientific journal Clinical Cancer Research, published...
2021-09-14 08:00 Regulatory
Biovica, active in cancer diagnostics, today announces that DiviTumTKa results from the large BioItaLEE study will be presented as a poster during the European Society for Medical Oncology (ESMO) meeting 16 to 21 September 2021. The results strengthen...
2021-09-13 08:07 Regulatory
Biovica, active in cancer diagnostics, today announced that the company’s expected timeline for its updated 510(k)-application to the US Food and Drug Administration (FDA) has been prolonged due to delay in response from FDA. As Biovica is still...

>4,500

Numbers of patients in studies

28

Publications

22

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No